Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Lux Health Tech Acquisition (LUXAU)
Upcoming IPO
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Atlas Crest Investment Corp. (ACICU)
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Bluescape Opportunities Acquisition (BOAC.U)
Absolute Software (ABST)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Nurix Therapeutics, Inc. (NRIX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging their extensive expertise in E3 ligases together with their proprietary DNA-encoded libraries, they have built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Their drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system, or UPS, to selectively decrease or increase cellular protein levels. Their wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Their lead drug candidate from their protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. They expect to file an IND for NX-2127 and commence a Phase 1 clinical trial thereafter. Their lead drug candidate from their E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. They expect to file an IND for NX-1607 and commence a Phase 1 clinical trial thereafter. Beyond these portfolios, they are advancing additional preclinical programs, either independently or through their established strategic collaborations with Sanofi and Gilead.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Arthur T. Sands Hans van Houte
Employees Founded
103 2009

Contacts

Address: 1700 Owens Street, Suite 205, San Francisco, CA 94158, US

Telephone: (415) 660-5320

Web page: http://www.nurixtx.com

IPO information

Expected Date 7/24/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $648.1
Revenues (MM) $19.5
Net Income (Loss) (MM) $-20.8

Voting

What do you think will happen with the NRIX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.8
Shares Revised (MM) 11
Expected offer amount (MM) $149.6
Realized offer amount(MM) $209
Underwriters
JP Morgan/ Piper Sandler/ Stifel
CO-Managers
Needham & Company

Sector: Healthcare

Tweets about $NRIX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats